Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 238-692-3
CAS number: 14643-87-9
Mortality and Clinical signs:
A moderate reduction in weight gain was
observed on day 1 after dose administration in male and female rats that
received 1000 mg/kg bw of test substance. Two female animals, one that
received 1000 mg/kg bw and one that received 333 mg/kg bw, were found
dead prior to their scheduled sacrifice. Irregular breathing and
wheezing were noted in three females from the 1000 mg/kg bw group. All
other animals appeared normal over the course of the study period.
Chromosomal damage in bone marrow
of male rats following acute exposure to acrylic acid:
Total no. of cells
Incidence of aberrations1[%]
Total no. of aberrations
Aberrations from severely damaged cells3
Includes chromatid and chromosome breaks and fragments.
Cells having more than 10 aberrations were counted as 10.
* p<0.05; ** p<0.01
Chromosomal damage in bone marrow
of female rats following acute exposure to acrylic acid:
Cells having pulverization or > 10 aberrations of any type.
Includes 10 aberrations contributed by 1 pulverized cell.
study was conducted to determine the ability of the test substance to
induce chromosomal aberrations in rats, according to a method similar to
OECD Guideline, in compliance with GLP. The test substance doses were
100, 333, and 1000 mg/kg bw (in a total volume of 3 mL/kg bw)
administered by oral gavage a single time. These doses were selected
based on the range finding study. Cyclophosphamide positive control
group received a single oral dose of mg/mL. A moderate reduction in
weight gain was observed on Day 1 after dose administration in male and
female rats that received 1000 mg/kg bw of test substance. Two female
animals, one that received 1000 mg/kg bw and one that received 333 mg/kg
bw, were found dead prior to their scheduled sacrifice. Irregular
breathing and wheezing were noted in three females from the 1000 mg/kg
bw group. All other animals appeared normal over the course of the study
period. Of the 250 metaphase bone marrow cells examined from each
animal, no significant increase in chromatid and chromosome breaks or
structural rearrangements were noted for test substance. The results of
the study indicate that test substance at these dose levels did not
induce detectable chromosomal aberrations after oral administration.
Under the study conditions, the test substance was not considered to be
genotoxic to rat by oral administration in chromosomal aberration assay
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
På den här webbplatsen används kakor. Syftet är att optimera din upplevelse av den.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again